Relief Cardiovascular is a privately held medical device company and an inQB8 Medical Technologies portfolio company focused on improving outcomes for patients with heart failure. Its flagship product, the Relief System, is a transcatheter smart implant that uses a "puller" mechanism and integrated sensors to autonomously capture renal vein pressures and multiparametric data. The system is designed to both monitor renal pressures and therapeutically modulate them, providing physicians actionable data to optimize fluid management—including for diuretic-resistant heart failure. The company plans to use new funding to advance product development and to initiate a first-in-human feasibility study to evaluate the safety and efficacy of the Relief System. Relief Cardiovascular has closed a $12M Series A to support these activities and is advancing toward human clinical studies. The company was founded and incubated within inQB8 Medical Technologies and is based in Irvine, Calif.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025